Form 4: ADMA Biologics Executive Reports Routine Tax Withholding on RSU Vesting

ADMA Biologics' COO and SVP of Compliance, Kaitlin M. Kestenberg-Messina, reported the withholding of 3,027 shares of common stock to cover tax obligations related to the vesting of restricted stock units.

Summary

• Kaitlin M. Kestenberg-Messina, COO and SVP, Compliance of ADMA Biologics, Inc., reported a transaction involving the company's common stock.
• On July 24, 2025, 3,027 shares of common stock were withheld by the Issuer at a price of $17.31 per share.
• This withholding was to satisfy mandatory tax requirements upon the vesting of restricted stock units (RSUs) and does not represent an open market sale.
• Following this transaction, the reporting person beneficially owns 487,398 shares of ADMA Biologics common stock.
• This total includes 294,524 unvested RSUs from grants on February 19, 2025 (77,784 units), April 1, 2024 (144,240 units), July 24, 2023 (15,000 units), March 6, 2023 (47,500 units), and March 7, 2022 (10,000 units), all vesting quarterly over four years.
• The beneficial ownership also includes 192,874 shares of common stock directly owned, which accounts for prior net settlements after tax withholdings from previously vested RSUs.

Sentiment

Score: 6

Explanation: The filing reports a routine tax withholding related to RSU vesting, which is a neutral event in itself. However, the underlying RSU vesting and the executive's continued significant beneficial ownership (including substantial unvested RSUs) are positive indicators of executive retention and alignment with shareholder interests, slightly elevating the sentiment.

Positives

• The transaction indicates the vesting of restricted stock units, which is a form of compensation for the executive, aligning their interests with shareholders.
• The executive continues to hold a significant number of shares and unvested RSUs, demonstrating continued commitment to the company.

Negatives

• No direct negatives are apparent from this routine tax withholding transaction.

Future Outlook

The filing details future vesting schedules for various RSU grants, indicating that a significant portion of the executive's compensation is tied to long-term performance and continued service, with vesting occurring quarterly on annual anniversaries over four years from their respective grant dates.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction related to executive compensation. It reflects standard practices in publicly traded companies where restricted stock units are a common component of executive pay, designed to align management incentives with shareholder value creation and retention. The specific transaction, a tax withholding upon RSU vesting, is a common administrative event in such compensation structures.

Related Party Transactions

• The transaction involves an executive (Kaitlin M. Kestenberg-Messina) and the company (ADMA Biologics, Inc.), which is a related party transaction in the context of executive compensation. However, it is a standard, non-discretionary event (tax withholding) related to a pre-existing compensation plan.

Stakeholder Impact

• Shareholders: Minimal direct impact. The withholding of shares for tax purposes is a routine administrative event. The underlying RSU vesting represents a planned dilution for compensation purposes, which is generally factored into valuation. The executive's continued significant equity holdings align their interests with shareholders.
• Employees: No direct impact on general employees.
• Customers/Suppliers/Creditors: No direct impact.

Next Steps

• Unvested RSUs granted on February 19, 2025, April 1, 2024, July 24, 2023, March 6, 2023, and March 7, 2022, will continue to vest in equal quarterly installments on each annual anniversary of their respective grant dates over four years, subject to the reporting person's continued service.

Key Dates

Recommendation

This Form 4 filing details a routine administrative transaction (shares withheld for tax upon RSU vesting) for an executive. It is not an an open market sale and does not indicate a change in the executive's long-term commitment or a significant shift in company fundamentals. While the executive continues to hold a substantial amount of equity, this specific filing does not provide new information that would warrant a change in investment thesis. Therefore, a "hold" recommendation is appropriate as it confirms ongoing executive compensation practices without presenting new catalysts for significant price movement.

Keywords

ADMA Biologics, ADMA, SEC Form 4, insider transaction, stock withholding, restricted stock units, RSU vesting, executive compensation, Kaitlin M. Kestenberg-Messina, beneficial ownership